Biotronik has launched a subcutaneous implantable leadless cardiac monitoring system for European patients with atrial fibrillation (AF) or unexplained syncope, bradycardia, sudden rate drop, asystole and tachycardia.
By using the company's ClearSense technology, the new device, BioMonitor, records three ECG channels from three-vector signal detection that produces precise and reliable arrhythmia monitoring.
The recordings are converted into a single ECG input signal which differentiates between a genuine signal and other artifacts such as myopotentials, caused due to body muscle contractions.
Leipzig University Heart Centre electrophysiology department director professor Gerhard Hindricks said, "Only long-term continuous monitoring with reliable arrhythmia detection offers the type of vital information necessary for physicians to make the right therapy decisions when managing patients with AF or unexplained syncope."
In addition, the cardiac device incorporates the company's home monitoring system, which provides daily remote data transfer without patient interaction.
Rostock University Hospital rhythmology and cardiology department director professor Dietmar Bänsch said, "BioMonitor supports physicians in every step of arrhythmia management, from diagnosis via monitoring to individualized therapy offering high quality solutions that benefit both physicians and patients."
